TY - JOUR
T1 - Influence of serum protein binding on the uptake and retention of idarubicin by sensitive and multidrug resistant human leukemic cells
AU - Kessel, M.
AU - Gieseler, F.
AU - Woodcock, B. G.
N1 - Funding Information:
Acknowledgements This work was supported by a grant from the Edith von Heyden legacy and represents a substantial part of the dissertation for the degree of Dr. med. by M. Kessel in the Faculty of Medicine, J.W. Goethe University Hospital, Frankfurt am Main, Germany. We are grateful for help and advice on the culture of HL-60 and HL-60-Vinc cells from the research group of Prof. D. Hoelzer, Department of Hematology and for help with the statistical evaluation from Dr. H. Ackermann, Zentrum der Medizinischen Informatik, University Hospital, Frankfurt am Main. We would also like to thank Dr. S. Kerpel-Fronius (Pharmacia & Upjohn, Erlangen, Germany) for supplying IDA and Dr. med. J. Kempeni and Dr. H. Kupper (Knoll AG, Ludwigshafen, Germany) for the generous gift of R-VRP.
PY - 1999
Y1 - 1999
N2 - Objective: The objectives of the-investigations were (1) to determine the binding characteristics of idarubicin (IDA) in human serum and cell culture solutions, (2) to determine the effect of protein binding on the uptake and retention of IDA by human leukemic cell lines in culture and the extent to which R-verapamil (R-VRP), an inhibitor of the P-glycoprotein (P- gp) transporter, can modulate these processes, and (3) to assess the importance of protein binding on cytostatic and chemosensitizer action in vivo. Methods: The protein binding of IDA was determined using equilibrium dialysis. Cell uptake of IDA was measured using sensitive and P-gp- containing resistant human leukemic cell lines (HL-60 and HL-60-Vinc) in vitro. IDA was assayed spectrophotofluorometrically. Results: In the incubation media examined, the free fraction of IDA varied more than seven- fold from approximately 60% in 15% fetal calf serum (FCS)/PBS to only 8% in human serum. Cellular uptake of IDA was approximately three times higher in medium containing low protein concentrations. R-VRP eliminated the difference in IDA uptake between resistant and sensitive cell lines and this was the case when the cells were incubated in solutions containing both high and low protein concentrations. However, R-VRP did not overcome the effect of high protein concentrations on IDA uptake. Conclusions: Plasma protein binding is an important determinant for cellular uptake of IDA in vitro. This should be taken into account when interpreting results of in vitro functional assays with patient material. Chemosensitizers such as R-VRP are effective in both high and low protein solutions. Investigations like these may be useful for evaluating cytostatic efficacy and chemosensitizer action in vivo.
AB - Objective: The objectives of the-investigations were (1) to determine the binding characteristics of idarubicin (IDA) in human serum and cell culture solutions, (2) to determine the effect of protein binding on the uptake and retention of IDA by human leukemic cell lines in culture and the extent to which R-verapamil (R-VRP), an inhibitor of the P-glycoprotein (P- gp) transporter, can modulate these processes, and (3) to assess the importance of protein binding on cytostatic and chemosensitizer action in vivo. Methods: The protein binding of IDA was determined using equilibrium dialysis. Cell uptake of IDA was measured using sensitive and P-gp- containing resistant human leukemic cell lines (HL-60 and HL-60-Vinc) in vitro. IDA was assayed spectrophotofluorometrically. Results: In the incubation media examined, the free fraction of IDA varied more than seven- fold from approximately 60% in 15% fetal calf serum (FCS)/PBS to only 8% in human serum. Cellular uptake of IDA was approximately three times higher in medium containing low protein concentrations. R-VRP eliminated the difference in IDA uptake between resistant and sensitive cell lines and this was the case when the cells were incubated in solutions containing both high and low protein concentrations. However, R-VRP did not overcome the effect of high protein concentrations on IDA uptake. Conclusions: Plasma protein binding is an important determinant for cellular uptake of IDA in vitro. This should be taken into account when interpreting results of in vitro functional assays with patient material. Chemosensitizers such as R-VRP are effective in both high and low protein solutions. Investigations like these may be useful for evaluating cytostatic efficacy and chemosensitizer action in vivo.
UR - http://www.scopus.com/inward/record.url?scp=0032817587&partnerID=8YFLogxK
U2 - 10.1007/s002280050642
DO - 10.1007/s002280050642
M3 - Journal articles
C2 - 10456486
AN - SCOPUS:0032817587
SN - 0031-6970
VL - 55
SP - 369
EP - 373
JO - European Journal of Clinical Pharmacology
JF - European Journal of Clinical Pharmacology
IS - 5
ER -